COVID-19: HHS Decree Looks To Shield Manufacturers From Future Liability Suits
Declaration provides legal immunity under emergency preparedness act
The US Department of Health and Human Services is offering some legal protection to developers of devices and diagnostics for use in the fight against the novel coronavirus.
You may also be interested in...
Manufacturers face risk of whistle-blower suits and government enforcement actions when emergency use authorizations expire and pandemic recedes, attorneys say, but interaction with FDA and documentation may mitigate risk.
Three attorneys got out their crystal balls to forecast what device industry sectors may come in for enforcement scrutiny related to the COVID-19 pandemic.
A $5bn emergency fund reimbursing US clinical laboratories for scaling up COVID-19 testing with lab-developed tests must be part of a $1tn Senate coronavirus aid and relief package, clinical lab group ACLA says. Other provisions already included in the draft bill address stockpiling of testing swabs, liability protection for medtech firms, a requirement for device makers to report supply chain shortages, the expanded use of telehealth, and preventing durable medical equipment payment reductions.